Free shipping on all orders over $ 500

XL019

Cat. No. M2566
XL019 Structure
Size Price Availability Quantity
10mM*1mL in DMSO USD 94  USD94 In stock
5mg USD 85  USD85 In stock
10mg USD 135  USD135 In stock
50mg USD 470  USD470 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2.

Customer Product Validations & Biological Datas
Source Anticancer Res (2017). Figure 2. XL019
Method fluorescence-activated cell sorting analyses
Cell Lines KBV20C cancer cells
Concentrations 5 μM
Incubation Time 24 h
Results As shown in Figure 2A, co-treatment with XL019 and vincristine increased the number of cells arrested in the G2 phase compared to that observed with single treatments with either agent.
Chemical Information
Molecular Weight 444.53
Formula C25H28N6O2
CAS Number 945755-56-6
Solubility (25°C) DMSO 15 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yu-Yi Chu-Farseeva, et al. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

[2] Ji Hyun Cheon, et al. P-gp Inhibition by XL019, a JAK2 Inhibitor, Increases Apoptosis of Vincristine-treated Resistant KBV20C Cells with Increased p21 and pH2AX Expression

[3] Allison Rosenthal, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

[4] Srdan Verstovsek, et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

[5] Constantine S Tam, et al. Investigational Janus kinase inhibitors

Related JAK Products
A-005

A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases.

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

JAK2/FLT3-IN-1 TFA

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively.

ZT55

ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM.

ZM39923

ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: XL019 supplier, JAK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.